GLP-1 Drugs and Kidney Disease - Who Benefits Most and What Comes Next

from GLP-1 Drugs and Kidney Disease · host Inception Point AI

Join host Julia Cartwright as she explores who benefits most from GLP-1 receptor agonists in kidney disease treatment. From the groundbreaking FLOW trial results in diabetic patients to emerging research in non-diabetic kidney disease, discover what four pillars of modern kidney care mean for patients facing declining function, and what cutting-edge biopsy studies reveal about these medications' future potential. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Episode metadata supplied by the publisher feed · Published Apr 7, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

GLP-1 Drugs and Kidney Disease - Who Benefits Most and What Comes Next

0:00 22:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GLP-1 Drugs and Kidney Disease?

This episode is 22 minutes long.

When was this GLP-1 Drugs and Kidney Disease episode published?

This episode was published on April 7, 2026.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this GLP-1 Drugs and Kidney Disease episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!